GRI Bio

GRI Bio Debt

The Debt of GRI Bio (GRI) as of Nov 3, 2026 is 71,000.00 USD. In the previous year, Debt was 119,000.00 USD — a change of -40.34% (lower).

Debt

71,000.00USD

YoY

-40.34%

Last updated:

In 2025, GRI Bio's total debt was 71,000.00 USD, a -40.34% change from the 119,000.00 USD total debt recorded in the previous year.

The GRI Bio Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
340,021.00 USD
Jan 1, 2020
336,000.00 USD
Jan 1, 2021
3.61 M USD
Jan 1, 2022
673,000.00 USD
Jan 1, 2023
14,000.00 USD
Jan 1, 2024
119,000.00 USD
Jan 1, 2025
71,000.00 USD
The GRI Bio Debt history
YEARDebtYoY
71,000.00USD-40.34%
119,000.00USD+750.00%
14,000.00USD-97.92%
673,000.00USD-81.38%
3.61 MUSD+975.60%
336,000.00USD-1.18%
340,021.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GRI Bio Stock analysis

What does GRI Bio do? GRI Bio, Inc. generates revenue through the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company focuses on advancing a pipeline of Natural Killer T (NKT) modulating therapies, including its lead program GRI-0621, a small molecule RAR-beta dual agonist for Idiopathic pulmonary fibrosis (IPF) treatment. GRI-0621 is formulated as a once-daily oral capsule targeting multiple fibrotic indications. The firm also develops GRI-0803, a novel activator of human Type 2 NKT cells for autoimmune disorders, initially targeting systemic lupus erythematosus. Additionally, GRI Bio holds a library of 500+ proprietary compounds addressing high-value indications with unmet medical needs. GRI Bio's primary customers are pharmaceutical companies and healthcare providers seeking innovative treatments for complex diseases. The company's lead asset GRI-0621 is positioned for clinical development in IPF, while GRI-0803 targets systemic lupus erythematosus. The firm's proprietary compound library supports potential partnerships and licensing agreements for high-value therapeutic areas. The company's business model relies on advancing its pipeline through clinical trials and securing strategic collaborations for drug development and commercialization. The company's revenue streams include potential licensing fees from pharmaceutical partners, milestone payments upon achieving clinical or regulatory milestones, and future royalties from commercialized products. GRI Bio's focus on NKT modulating therapies for inflammatory, fibrotic, and autoimmune diseases positions it to address significant unmet medical needs in these therapeutic areas. The firm's pipeline includes GRI-0621 for IPF and GRI-0803 for systemic lupus erythematosus, with additional compounds targeting other high-value indications. GRI Bio is one of the most popular companies on Eulerpool.

Debt Details

Understanding GRI Bio's Debt Structure

GRI Bio's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing GRI Bio's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to GRI Bio’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in GRI Bio’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about GRI Bio stock

Debt of GRI Bio is 71,000.00 USD in 2025.

Debt of GRI Bio changed from 119,000.00 USD to 71,000.00 USD, representing a -40.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt GRI Bio since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's GRI Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — GRI Bio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GRI Bio